Control of immune escaped human papilloma virus is regained after therapeutic vaccination

9Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

High-risk human papillomaviruses infect the basal cells of human epithelia. There it deploys several mechanisms to suppress pathogen receptor recognition signalling, impeding the immune system to control viral infection. Furthermore, infected cells become more resistant to type I and II interferon, tumour necrosis factor-α and CD40 activation, via interference with downstream programs halting viral replication or regulating the proliferation and cell death. Consequently, some infected individuals fail to raise early protein-specific T-cell responses that are strong enough to protect against virus-induced premalignant disease and ultimately cancer. Therapeutic vaccines triggering a strong T-cell response against the early proteins can successfully be used to treat patients at the premalignant stage but combinations of different treatment modalities are required for cancer therapy.

Cite

CITATION STYLE

APA

Ma, W., Melief, C. J., & van der Burg, S. H. (2017, April 1). Control of immune escaped human papilloma virus is regained after therapeutic vaccination. Current Opinion in Virology. Elsevier B.V. https://doi.org/10.1016/j.coviro.2017.02.005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free